环硅酸锆钠散治疗慢性心力衰竭患者高钾血症的临床效果观察
Clinical efficacy of sodium zirconate cyclosilicate powder in the treatment of hyperkalemia in patients with chronic heart failure
刘波 1程志群 1俞海峰2
作者信息
- 1. 313000 湖州市中心医院(浙江大学医学院附属湖州医院)肾内科
- 2. 313000 湖州市中心医院(浙江大学医学院附属湖州医院)心内科
- 折叠
摘要
目的 观察环硅酸锆钠散对慢性心力衰竭患者高钾血症的治疗效果及安全性.方法 选择2021年 11月至2022年11月在湖州市中心医院接受环硅酸锆钠散治疗高钾血症的慢性心力衰竭患者42例,其中男24例,女18例,年龄45～85(65.0±8.9)岁.所有患者均接受10 g、3次/d的硅酸锆钠散治疗,分析药物降钾效果及不良反应.结果 环硅酸锆钠散治疗 2h后,血钾水平由 5.68(5.46,5.85)mmol/L降至 5.11(4.97,5.24)mmol/L,下降 0.60(0.49,0.72)mmol/L.用药24h后血钾水平为4.34(4.03,4.50)mmol/L,下降1.35(1.24,1.62)mmol/L.与治疗前相比,治疗2、24 h后血钾水平均明显降低(均P＜0.05).用药24h后发生低钾血症8例(19.0%),根据治疗后血钾水平分为低钾血症组、非低钾血症组,两组患者治疗前血钾水平[5.47(5.35,5.62)mmol/L比5.78(5.50,5.90)mmol/L]比较差异有统计学意义(Z=2.499,P=0.011).所有患者未见其他药物相关不良反应.结论 环硅酸锆钠散可在短时间内有效降低慢性心力衰竭合并的高血钾.轻度高钾血症患者治疗时有发生低钾血症风险.
Abstract
Objective To investigate the efficacy and safety of sodium zirconium cyclosilicate(SZC)powder in the treatment of hyperkalemia in patients with chronic heart failure.Methods A total of 42 patients with chronic heart failure and hyperkalemia who received SZC powder therapy in Huzhou Central Hospital from November 2021 to November 2022 were included.24 patients were male,18 were female and the age was 45-85(65.0±8.9)years old.All patients were given SZC powder at a dose of 10g thrice daily.The potassium lowering effect and adverse reactions of the drug were analyzed.Results Serum potassium levels decreased from 5.68(5.46,5.85)mmol/L to 5.11(4.97,5.24)mmol/L,a decrease of 0.60(0.49,0.72)mmol/L,2 hours later after treatment,and decreased to 4.34(4.03,4.50)mmol/L,a decreased of 1.35(1.24,1.62)mmol/L,24 hours later.Compared with before treatment,blood potassium levels significantly decreased after 2 and 24 hours of treatment(both P＜0.05).Hypokalemia developed in 8 case after 24 hours of treatment(19.0% ).The patients were divided into hypokalemia group and non-hypokalemia group based on post-treatment serum potassium,with a significant difference of pre-treatment serum potassium between the two groups[5.47(5.35,5.62)mmol/L vs.5.78(5.50,5.90)mmol/L,Z=2.499,P=0.011).No other drug-related adverse events were observed.Conclusion SZC powder can effectively reduce serum potassium of patients with chronic heart failure and hyperkalemia in a short time.Patients with mild hyperkalemia have the risk of hypokalemia after treatment.
关键词
慢性心力衰竭/高钾血症/环硅酸锆钠散Key words
Chronic heart failure/Hyperkalemia/Sodium zirconium cyclosilicate powder lization引用本文复制引用
基金项目
湖州市科技局公益性应用研究项目(2022GYB14)
出版年
2024
NETL
NSTL
维普
万方数据